Department of Clinical Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
PLoS One. 2010 Aug 26;5(8):e12381. doi: 10.1371/journal.pone.0012381.
KIR2DS5 gene encodes an activating natural killer cell receptor whose ligand is not known. It was recently reported to affect the outcome of hematopoietic stem cell transplantation.
METHODOLOGY/PRINCIPAL FINDINGS: In our studies on KIR2DS5 gene associations with human diseases, we compared the frequencies of this gene in patients and relevant controls. Typing for KIR2DS5 gene was performed by either individual or multiplex polymerase chain reactions which, when compared in the same samples, gave concordant results. We noted an apparently protective effect of KIR2DS5 gene presence in several clinical conditions, but not in others. Namely, this effect was observed in ankylosing spondylitis (p=0.003, odds ratio [OR]=0.47, confidence interval [CI]=0.28-0.79), endometriosis (p=0.03, OR=0.25, CI = 0.07-0.82) and acute rejection of kidney graft (p=0.0056, OR=0.44, CI=0.24-0.80), but not in non-small-cell lung carcinoma, rheumatoid arthritis, spontaneous abortion, or leukemia (all p>0.05). In addition, the simultaneous presence of KIR2DS5 gene and HLA-C C1 allotype exhibited an even stronger protective effect on ankylosing spondylitis (p=0.0003, OR=0.35, CI=0.19-0.65), whereas a lack of KIR2DS5 and the presence of the HLA-C C2 allotype was associated with ankylosing spondylitis (p=0.0017, OR=1.92, CI=1.28-2.89), whereas a lack of KIR2DS5 and presence of C1 allotype was associated with rheumatoid arthritis (p=0.005, OR=1.47, CI=1.13-1.92). The presence of both KIR2DS5 and C1 seemed to protect from acute kidney graft rejection (p=0.017, OR=0.47, CI=0.25-0.89), whereas lack of KIR2DS5 and presence of C2 seemed to favor rejection (p=0.0015, OR=2.13, CI=1.34-3.37).
CONCLUSIONS/SIGNIFICANCE: Our results suggest that KIR2DS5 may protect from endometriosis, ankylosing spondylitis, and acute rejection of kidney graft.
KIR2DS5 基因编码一种激活的自然杀伤细胞受体,其配体尚不清楚。最近有报道称其影响造血干细胞移植的结果。
方法/主要发现:在我们对 KIR2DS5 基因与人类疾病关联的研究中,我们比较了患者和相关对照中该基因的频率。通过个体或多重聚合酶链反应进行 KIR2DS5 基因分型,在相同样本中比较时,结果一致。我们注意到该基因在几种临床情况下存在明显的保护作用,但在其他情况下则没有。具体来说,这种效应在强直性脊柱炎(p=0.003,优势比[OR]=0.47,置信区间[CI]=0.28-0.79)、子宫内膜异位症(p=0.03,OR=0.25,CI=0.07-0.82)和肾移植急性排斥(p=0.0056,OR=0.44,CI=0.24-0.80)中观察到,但在非小细胞肺癌、类风湿关节炎、自然流产或白血病中则没有(均 p>0.05)。此外,KIR2DS5 基因和 HLA-C C1 同种型的同时存在对强直性脊柱炎表现出更强的保护作用(p=0.0003,OR=0.35,CI=0.19-0.65),而缺乏 KIR2DS5 和存在 HLA-C C2 同种型与强直性脊柱炎相关(p=0.0017,OR=1.92,CI=1.28-2.89),而缺乏 KIR2DS5 和存在 C1 同种型与类风湿关节炎相关(p=0.005,OR=1.47,CI=1.13-1.92)。同时存在 KIR2DS5 和 C1 似乎可以预防急性肾移植排斥(p=0.017,OR=0.47,CI=0.25-0.89),而缺乏 KIR2DS5 和存在 C2 似乎有利于排斥(p=0.0015,OR=2.13,CI=1.34-3.37)。
结论/意义:我们的结果表明,KIR2DS5 可能对子宫内膜异位症、强直性脊柱炎和肾移植急性排斥有保护作用。